

HR 4866

National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2020

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Oct 28, 2019

Current Status: Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and

Latest Action: Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sep 22, 2020)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/4866>

Sponsor

Name: Rep. Pallone, Frank, Jr. [D-NJ-6]

Party: Democratic • **State:** NJ • **Chamber:** House

Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Guthrie, Brett [R-KY-2]	R · KY		Oct 28, 2019
Rep. Spanberger, Abigail Davis [D-VA-7]	D · VA		May 12, 2020

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Reported by	Mar 11, 2020
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Sep 22, 2020

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 HR 14	Related bill	Nov 2, 2020: Referred to the Subcommittee on Railroads, Pipelines, and Hazardous Materials.
116 HR 6800	Related bill	Jul 23, 2020: Committee on Small Business and Entrepreneurship. Hearings held. Hearings printed: S.Hrg. 116-517.
116 HR 6379	Related bill	Mar 23, 2020: Referred to the Committee on Appropriations, and in addition to the Committees on the Budget, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2020

This bill directs the Food and Drug Administration (FDA) to designate qualified institutions of higher education as National Centers of Excellence in Continuous Pharmaceutical Manufacturing and to provide grants to the centers. Each designated center must conduct research on continuous manufacturing technologies and must share information from such research with the FDA. (Currently, most drug production involves batch manufacturing, which typically takes longer than continuous manufacturing processes.)

Actions Timeline

- **Sep 22, 2020:** Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- **Sep 21, 2020:** Mrs. Dingell moved to suspend the rules and pass the bill, as amended.
- **Sep 21, 2020:** Considered under suspension of the rules. (consideration: CR H4616-4618)
- **Sep 21, 2020:** DEBATE - The House proceeded with forty minutes of debate on H.R. 4866.
- **Sep 21, 2020:** Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
- **Sep 21, 2020:** On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4616-4617)
- **Sep 21, 2020:** Motion to reconsider laid on the table Agreed to without objection.
- **Sep 17, 2020:** Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-513.
- **Sep 17, 2020:** Placed on the Union Calendar, Calendar No. 413.
- **Jul 15, 2020:** Committee Consideration and Mark-up Session Held.
- **Jul 15, 2020:** Ordered to be Reported (Amended) by Voice Vote.
- **Mar 11, 2020:** Subcommittee Consideration and Mark-up Session Held.
- **Mar 11, 2020:** Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .
- **Oct 29, 2019:** Referred to the Subcommittee on Health.
- **Oct 28, 2019:** Introduced in House
- **Oct 28, 2019:** Referred to the House Committee on Energy and Commerce.